Illumina, Inc.

ILMN

Illumina, Inc.
Current price$263.31
5 days change+1.46%
ILMN intrinsic value

$301.24

+14.41%
Strong SellStrong Buy

Moderate Buy

IDbyDNA and Illumina Partner to Deliver NGS Infectious Disease Solutions

IDbyDNA and Illumina Partner to Deliver NGS Infectious Disease Solutions

IDbyDNA announces a global strategic partnership with Illumina to bring next-generation sequencing based workflows to the global microbiology market.

Why Is Illumina (ILMN) Down 12.2% Since Last Earnings Report?

Why Is Illumina (ILMN) Down 12.2% Since Last Earnings Report?

Illumina (ILMN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Illumina Files Additional Patent Infringement Suit Against BGI in the U.S.

Illumina Files Additional Patent Infringement Suit Against BGI in the U.S.

Illumina Files Additional Patent Infringement Suit Against BGI in the U. S.

Illumina earnings report beats estimated earnings per share by 7.06%, but misses revenue by 4.3%

Illumina earnings report beats estimated earnings per share by 7.06%, but misses revenue by 4.3%

Illumina reported earnings per share of $1. 7 on revenue of $907M, the consensus between analysts was $1.58 per share on revenue of $946M.

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2019

Illumina Reports Financial Results for Fourth Quarter and Fiscal Year 2019

Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the fourth quarter and fiscal year 2019. Fourth quarter 2019 results: Revenue

Can Sequencing Products Aid Illumina (ILMN) in Q4 Earnings?

Can Sequencing Products Aid Illumina (ILMN) in Q4 Earnings?

Illumina (ILMN) is upbeat about fourth-quarter and fiscal 2019 results after a strong third-quarter performance.

Illumina News: ILMN Stock 4% Lower on Weak 2020 Outlook

Illumina News: ILMN Stock 4% Lower on Weak 2020 Outlook

Illumina (ILMN) news for Monday includes ILMN stock falling on a weak outlook for 2020, as well as some other news about a deal.

ArcherDX and Illumina Partner for Future to Co-Market Portfolio of Planned In-Vitro Diagnostic (IVD) Tests

ArcherDX and Illumina Partner for Future to Co-Market Portfolio of Planned In-Vitro Diagnostic (IVD) Tests

/PRNewswire/ -- ArcherDX, Inc. today announced a non-exclusive, multi-year partnership with Illumina, Inc. (NASDAQ: ILMN) intended to broaden access of next. . .

Illumina Stock Could Illuminate This Healthcare ETF | ETF Trends

Illumina Stock Could Illuminate This Healthcare ETF | ETF Trends

Biotech firm Illumina, Inc. (NASDAQ: ILMN) scrapped a merger with Pacific Biosciences, but there's still a lot to like about Illumina

Illumina, Pacific Biosciences drop $1.2 billion merger agreement

Illumina, Pacific Biosciences drop $1.2 billion merger agreement

Illumina Inc. and Pacific Biosciences of California Inc. on Thursday said they have agreed to drop plans to merge. Under the merger agreement, announced Nov. . . .

Illumina Inks Deal With ArcherDX to Deliver NGS-Based IVD Kits

Illumina Inks Deal With ArcherDX to Deliver NGS-Based IVD Kits

Under the contract, ArcherDX will develop IVD tests that will run on Illumina's (ILMN) NextSeq 550Dx System.

Investors Should Wait for Sky-High Valuations on Illumina Stock to Deflate

Investors Should Wait for Sky-High Valuations on Illumina Stock to Deflate

You pay a high price for a company with near monopoly like Illumina. ILMN stock has 70% market share, but Its valuation is too high.

Why Illumina Stock Is Sinking Today | The Motley Fool

Why Illumina Stock Is Sinking Today | The Motley Fool

Questions about near-term prospects are weighing on the gene-sequencing stock.

Illumina earnings report beats estimated earnings per share by 27.46%, but misses revenue by 3.94%

Illumina earnings report beats estimated earnings per share by 27.46%, but misses revenue by 3.94%

Illumina reported earnings per share of $1. 93 on revenue of $838M, the consensus between analysts was $1.4 per share on revenue of $871M.

Illumina (ILMN) Inks Deal to Commercialize NGS-Based IVD Kits

Illumina (ILMN) Inks Deal to Commercialize NGS-Based IVD Kits

Illumina (ILMN) aims to expand access to NGS-based IVD test kits and improve patient outcomes through the new partnership deal.

Illumina, Broad Institute Partner on Secondary Genomic Analysis

Illumina, Broad Institute Partner on Secondary Genomic Analysis

The tie-up between Illumina (ILMN) and the Broad Institute of MIT and Harvard is expected to enhance the company's portfolio of sequencing products.

Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?

Will Illumina (ILMN) Beat Estimates Again in Its Next Earnings Report?

Illumina (ILMN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Illumina (ILMN) Inks Deal to Develop Distributable Test Kits

Illumina (ILMN) Inks Deal to Develop Distributable Test Kits

Illumina (ILMN) aims to expand access to genomic-based testing and improve patient outcome through the new partnership deal.

Illumina (ILMN) Gains on Product Pipeline, Global Footprint

Illumina (ILMN) Gains on Product Pipeline, Global Footprint

Illumina (ILMN) pins high hopes on almost a dozen new drugs unveiled with a predictive biomarker (nine of which are already approved for oncology indications).

Loading ...